Company intelligence / Profile preview

Isotopia Molecular Imaging

Petah Tikva, Central District, Israelisotopia-global.com ↗

Ownership: Private
Employees: ~89
Development stage: Commercial

Overview

The company has received marketing authorization in the Netherlands for Isoprotrace®, a PSMA-11 kit for prostate cancer diagnosis. They are a major global supplier of GMP-grade Lutetium-177 for therapeutic use in cancer treatment.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalsPET and SPECT radiotracersRadioactive isotopes
Industry: Protein Biomarker Diagnostics

Drug pipeline

2 assets

lutetium-177

Commercial

Indications: Cancer, Prostate Cancer, Neuroendocrine Tumors

1 more asset in the full pipeline.

Request access →

Partnerships

Billev Pharma (as marketing authorization holder)

Beyond the preview

Go deeper on Isotopia Molecular Imaging.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Isotopia Molecular Imaging.

Explore the full profile